论文部分内容阅读
目的观察罗格列酮治疗2型糖尿病的心血管安全性。方法选取2008年3月-2011年3月收治的2型糖尿病患者120例,随机分为治疗组和对照组各60例。治疗组给予马来酸罗格列酮4mg,每天1次,联合精蛋白锌生物合成人胰岛素注射液预混30R;对照组仅予精蛋白锌生物合成人胰岛素注射液预混30R治疗,根据血糖要求调整个体化的胰岛素给药剂量。每3个月监测患者体质量、血压、心脏彩超、心电图,监测期为2年,数据进行统计分析。结果治疗后,治疗组的患者体质量与对照组比较差异无统计学意义(P>0.05),治疗组发生下肢水肿的比例与对照组比较差异亦无统计学意义(P>0.05);治疗组的E/A在1~2之间,治疗组的左室射血分数(LVEF)、左室舒张末期内径(LVEDD),均与对照组比较差异无统计学意义(P>0.05),监测期内无异常心电图。结论罗格列酮可引起下肢水肿,但发生率较低,在监测期内未增加心力衰竭和心肌梗死的风险。
Objective To observe the cardiovascular safety of rosiglitazone in the treatment of type 2 diabetes mellitus. Methods A total of 120 patients with type 2 diabetes mellitus were selected from March 2008 to March 2011, and randomly divided into treatment group (60 cases) and control group (60 cases). Treatment group were given rosiglitazone maleate 4mg, 1 day, combined protamine zinc biosynthesis human insulin injection premixed 30R; control group only to protamine zinc biosynthesis human insulin injection premixed 30R treatment, according to the blood sugar Requires adjustment of individualized insulin dosage. Body mass, blood pressure, echocardiography and electrocardiogram were monitored every 3 months, and the monitoring period was 2 years. The data were analyzed statistically. Results After treatment, there was no significant difference in body mass between the treatment group and the control group (P> 0.05), and there was no significant difference between the treatment group and the control group (P> 0.05) Of E / A was between 1 and 2, LVEF and LVEDD in the treatment group were not significantly different from those in the control group (P> 0.05). The monitoring period No abnormal ECG. Conclusions Rosiglitazone can cause lower extremity edema, but the incidence is low. During the monitoring period, it did not increase the risk of heart failure and myocardial infarction.